Adicet Bio

$12.99 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Adicet Bio

Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.

Stock Analysis

last close $11.93
1-mo return -27.7%
3-mo return 39.5%
avg daily vol. 304.06T
52-week high 18.49
52-week low 6.25
market cap. $456M
forward pe -
annual div. -
roe -33%
ltg forecast -
dividend yield -
annual rev. $10M
inst own. 61%
baraka

Subscribe now for daily local and international financial news

Subscribe